Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Carlos A. Vargas, MD
Advertisement
Articles by Carlos A. Vargas, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
2
VOLGA: Durvalumab plus enfortumab vedotin improves EFS, OS in MIBC
3
Adding perioperative pembrolizumab to chemotherapy does not improve EFS in MIBC
4
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
5